Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | NAAA | Q02083 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.49 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | MLYCD | O95822 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13918749 | 0.90 | KDM4E (0.70) | KDM4EKMT2AL3MBTL1ALDH1A1NAAA | |
| SCHEMBL95136 | 0.89 | L3MBTL1 (0.63) | KMT2AL3MBTL1ALDH1A1NAAADRD2 | |
| SCHEMBL5044694 | 0.86 | L3MBTL1 (0.73) | KMT2AL3MBTL1ALDH1A1NAAADRD2 | |
| SCHEMBL6717371 | 0.86 | L3MBTL1 (0.73) | KMT2AL3MBTL1ALDH1A1NAAADRD2 | |
| SCHEMBL5039664 | 0.86 | L3MBTL1 (0.73) | KMT2AL3MBTL1ALDH1A1NAAADRD2 | |
| SCHEMBL3053255 | 0.85 | KMT2A (0.57) | KDM4EKMT2AL3MBTL1ALDH1A1NAAA | |
| SCHEMBL14350257 | 0.84 | KDM4E (0.64) | KDM4EKMT2AL3MBTL1ALDH1A1NAAA | |
| SCHEMBL96158 | 0.84 | CA12 (0.50) | KMT2AL3MBTL1ALDH1A1POLBNPC1 | |
| SCHEMBL10789854 | 0.82 | KDM4E (0.62) | KDM4EKMT2AL3MBTL1ALDH1A1NAAA | |
| SCHEMBL166778 | 0.82 | KDM4E (0.62) | KDM4EKMT2AL3MBTL1ALDH1A1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| CN-101489555-A | Nf-kappa | OTSUKA PHARMA CO LTD (JP) | 2009-07-22 | — | — | CN | disclosed |
| WO-2007119600-A9 | CARBAZOLE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2008-05-02 | — | — | WO | disclosed |
| WO-2007119600-A1 | CARBAZOLE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-10-25 | — | — | WO | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1797082-A1 | CARBOSTYRIL COMPOUND | Otsuka Pharmaceutical Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006035954-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | KDM4E 1125/4885KMT2A 1059/4885L3MBTL1 1099/4885 |
| US-20070179173-A1 | Carbostyril compound | GTF2F1, F3, GTF2F2 | KDM4E 3919/4885KMT2A 2732/4885L3MBTL1 262/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | KDM4E 3919/4885KMT2A 2732/4885L3MBTL1 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.